The document outlines three key initiatives and two support packages focused on dementia and cognitive impairment, including the development of clinical quality registries and the expansion of memory clinics and trial sites. It also details the infrastructure to support these initiatives and the associated research study on aging, highlighting significant enrollment and data accessibility for researchers. The document lists various international partners and expressions of interest for additional data access.

2. Three Initiatives and Two Support Packages

3. ADNeT in a Nutshell
• Clinical Quality Registry (CQR) for newly diagnosed
dementia or “mild cognitive impairment”
• Memory Clinics – expand, standardize and support
• Clinical Trial sites – expand and support
• Longitudinal (n=4,000) and Trial ready (n=500) cohorts –
blood, MRI, cognition, amyloid and tau PET, +/- CSF every 2 years

4. ADNeT Tech
1.Provide IT infrastructure and support for the key ADNeT initiatives
2.Develop and harmonise innovative diagnostic technologies (i.e. PET
and MRI imaging and blood and CSF biomarkers).

5. The Australian Imaging Biomarkers and Lifestyle
Study of Ageing
.
Commenced late 2006

6. 0m 18m 36m 54m 72m 90m 108m 126m
CN 1476 1034 776 684 523 419 376 219
MCI 394 174 107 79 59 34 28 19
AD 427 286 219 127 68 44 30 6
Other 17 7 10 12 8 6 3 2
Total 2314 1501 1112 902 658 503 437 246
Cumulative
Withdrawn 468 681 838 986 1066 1129 1153
% Follow up
complete 81% 68% 61% 49% 40% 37% 21%
AIBL cohort : Number of assessments

7. 3,500 researchers granted access to AIBL data via
www.adni.loni.usc.edu
Includes access granted to 112 companies e.g.:
Abbott Labs, Abiant, ADM diagnostics, Astra Zeneca, Avid, BioClinica, Biogen Idec, Bristol-Myers Squibb, Cogstate Cytokinetics, Eisai, Elan, Eli Lilly, GE Health Care,
General Resonance, Genetech, Imorphics, Iris Biotechnologies, Janssen, Johnson Johnson, M and M Scientific, Merck & Co, Mimvista, Pentara Corp, Pfizer, Philips,
Predixion software, Rancho Biosciences, Servier, Siemens, Soft team solutions, UCB, United Biosource Corp.
AIBL has also received 250 Expressions of Interest for access to more detailed data.
Bangladesh
China
Hong Kong
India
Indonesia
Japan
Kyrgyzstan
Malaysia
Pakistan
Philippines
Singapore
South Korea
Taiwan
Thailand
Australia
New Zealand
Iran
Iraq
Israel
Saudi Arabia
Turkey
Canada
Cuba
Martinique
Mexico
Puerto Rico
USA
Argentina
Bolivia
Brazil
Chile
Colombia
Ecuador
Guyana
Netherlands Antilles
Peru
Uruguay
Austria
Belgium
Bulgaria
Cyprus
Denmark
Estonia
Finland
France
Algeria
Egypt
Ghana
Morocco
Nigeria
Tunisia
Germany
Greece
Hungary
Ireland
Italy
Lithuania
Luxembourg
Macedonia
Netherlands
Norway
Poland
Portugal
Romania
Russia
Serbia
Slovakia
Slovenia
Spain
Sweden
Switzerland
Ukraine
UK